Tevogen Bio files patent for T cell vaccine targeting entire viral genome, enhancing immune response against mutations and viral infections.
Quiver AI Summary
Tevogen Bio, a clinical-stage immunotherapy biotech company, announced the filing of a new patent for its T cell vaccine designed to stimulate T cell responses against a virus's entire genome, aiming to reduce risks from mutations. Utilizing the company's Tevogen.AI-powered PredicTcell technology, the vaccine targets viral peptides to enhance immune responses, complementing existing treatments under development. Tevogen Bio's approach is currently focused on national security but may later expand to broader applications. CEO Ryan Saadi emphasized the importance of public trust and transparency during vaccine development. The company holds multiple patents related to its technology and is committed to making its therapeutics accessible while addressing significant healthcare challenges.
Potential Positives
- Tevogen Bio filed a new patent for its under-development T cell vaccine, demonstrating innovation and a commitment to advancing immunotherapy solutions.
- The vaccine targets the entire viral genome, potentially mitigating the risk of mutations that could evade immune detection, positioning Tevogen as a forward-thinking leader in vaccine development.
- The company reported positive safety data from its proof-of-concept clinical trial, which reinforces the credibility of its product candidates.
- Tevogen Bio's leadership emphasizes transparency and public involvement during vaccine development, which may enhance trust among stakeholders and the general public.
Potential Negatives
- Potential dependency on raising additional capital, which may not be available on acceptable terms.
- Risks associated with uncertainties in clinical trials and potential regulatory hurdles that could impede product development and commercialization.
- Significant reliance on forward-looking statements that may not materialize, impacting investor trust and market performance.
FAQ
What is Tevogen Bio's new T cell vaccine designed to do?
It aims to stimulate T cell responses against the entire genome of selected viruses, mitigating the risk of mutations.
How does this vaccine differ from traditional vaccines?
Unlike many vaccines focusing on B cell responses, this vaccine targets T cell responses across the entire viral genome.
What technology powers the vaccine development at Tevogen Bio?
The development utilizes Tevogen.AI-powered PredicTcell technology to identify peptides that stimulate T cell responses.
What are the primary applications of Tevogen Bio's T cell vaccine?
Initially prioritizing national security, it may later expand to broader public health applications against viral infections.
How does Tevogen Bio ensure transparency during vaccine development?
CEO Ryan Saadi emphasizes open dialogue and public involvement to build trust in the vaccine development process.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TVGN Insider Trading Activity
$TVGN insiders have traded $TVGN stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $TVGN stock by insiders over the last 6 months:
- NEAL FLOMENBERG (See Remarks) has made 0 purchases and 4 sales selling 1,292,417 shares for an estimated $1,997,338.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TVGN Hedge Fund Activity
We have seen 30 institutional investors add shares of $TVGN stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PORTLAND GLOBAL ADVISORS LLC removed 1,854,517 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,910,152
- POLAR ASSET MANAGEMENT PARTNERS INC. removed 1,577,387 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,624,708
- CANTOR FITZGERALD, L. P. removed 603,691 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $621,801
- BLACKROCK, INC. added 370,936 shares (+160.6%) to their portfolio in Q4 2024, for an estimated $382,064
- HGC INVESTMENT MANAGEMENT INC. removed 223,077 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $229,769
- UBS GROUP AG added 174,031 shares (+1644.9%) to their portfolio in Q4 2024, for an estimated $179,251
- NEW YORK STATE COMMON RETIREMENT FUND removed 119,500 shares (-94.5%) from their portfolio in Q4 2024, for an estimated $123,085
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Vaccine is intended to stimulate T cell responses against targets across the
entire genome of the selected virus,
similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations.
Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Tevogen Bio.
Powered by Tevogen Bio’s artificial intelligence initiative, Tevogen.AI.
The company hopes to address public concerns about inoculation during vaccine development.
WARREN, N.J., March 10, 2025 (GLOBE NEWSWIRE) --
Tevogen Bio
(“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq:
TVGN
), a clinical-stage specialty immunotherapy biotech company, today announced the filing of a new patent with the U.S. Patent and Trademark Office (USPTO) for its under-development T cell vaccine. Unlike many vaccines that primarily induce a B cell response, Tevogen Bio’s design aims to leverage the Company’s proprietary Tevogen.AI-powered PredicTcell technology to identify peptides which stimulate a T cell response.
A key differentiator of this vaccine is its ability to target the
entire viral genome,
much like the Company’s lead product candidate, TVGN 489. This strategy helps mitigate the risk posed by mutations that might otherwise evade immune detection when only one protein or segment of the virus is targeted.
The development of this vaccine leverages Tevogen Bio’s established technology and will not impact previously announced launch year topline forecasts of $1 billion each for Tevogen Bio Oncology and Specialty Care.
“While our T cell vaccine development currently prioritizes national security and equipping the U.S. military against biological threats, its use can be expanded to broader applications if circumstances call for it,” said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. “The success of any public health measure relies on the trust and support of the people it is meant to protect, and just as I value open dialogue with our retail shareholders, I am personally committed to ensuring transparency and active public involvement throughout the development process,” added Dr. Saadi.
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
